Clinical trials: Cytokine Storm
COVID-19, Cytokine Storm
CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19
COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2. COVID-19 causes life threatening complications known as Cytokine Release Syndrome or Cytokine Storm and Acute Respiratory Distress…
- Conditions
- COVID-19, Cytokine Storm, Acute Respiratory Distress Syndrome
- Trial name
- CORONA (NCT04378244)
- Testing
- DeltaRex-G
- Sponsor
- Aveni Foundation
Coronavirus Infection, COVID
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
In December 2019 in the city of Wuhan in China, a series of patients with unclear pneumonia was noticed, some of whom have died of it.
- Conditions
- Coronavirus Infection, COVID, SARS-CoV 2, Respiratory Failure
- Trial name
- CYCOV-II (NCT04385771)
- Testing
- vv-ECMO + cytokine adsorption (Cytosorb adsorber), vv-ECMO only (no cytokine adsorption)
- Where
- 3 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Dr. Alexander Supady
Covid19, Ketogenic Dieting
Eucaloric Ketogenic Diet in COVID-19 Cytokine Storm Syndrome
Covid 19 pandemia is causing millions of deaths worldwide. To date, the evidence gathered suggests that the subgroup of patients who present the most serious clinical feature of COVID-19 could have a "cytokine storm syndrome"…
- Trial name
- ketocovidiet (NCT04492228)
- Testing
- Ketogenic diet
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Ospedale Policlinico San Martino
Burns, Multiple Organ Failure
Early Haemadsorption in Major Burns
Major deep burns (>20% body surface, involving deep skin layers) and associated severe inflammatory reaction and their complication are one of the biggest challenge of intensive care.
- Conditions
- Burns, Multiple Organ Failure, Shock, Organ Dysfunction Syndrome, Multiple
- Trial name
- NCT04195126
- Testing
- CytoSorb haemadsorption device
- Where
- Hungary
- Volunteers
- 20 people
- Sponsor
- University of Pecs
Covid19, Cytokine Storm
Anakinra, COVID-19, Cytokine Storm
The clinical syndrome associated with infection of the Coronavirus Disease 2019 (COVID-19) is notable for its variable clinical expression.
- Conditions
- Covid19, Cytokine Storm, Mechanical Ventilation Complication
- Trial name
- SOBI (NCT04603742)
- Testing
- Anakinra, 0.9% Saline
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Cytokine Release Syndrome
Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy
This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS).
- Trial name
- NCT05905328
- Testing
- CTO1681 10 µg, CTO1681 20 μg, CTO1681 30 μg
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- CytoAgents, Inc.
Infection After Transfusion, Transfusion-related Immunomodulation Reaction
Blood Transfusions and Immune Response
We have previously reported the results of the primary and secondary outcomes of a randomized study aiming to investigate the impact of a restrictive transfusion protocol on the magnitude of reduction in blood transfusion in a…
- Conditions
- Infection After Transfusion, Transfusion-related Immunomodulation Reaction, Cytokine Storm, Surgery
- Trial name
- NCT02020525
- Testing
- restrictive transfusion strategy, liberal transfusion strategy
- Where
- Greece
- Volunteers
- 58 people
- Sponsor
- Aretaieion University Hospital
Covid-19
Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm
This is a Phase II pilot exploratory study designed to investigate if prophylactic treatment with short term steroids administered to high risk Covid-19 patient might prevent cytokine storm and progression to respiratory failure.
- Trial name
- NCT04355247
- Testing
- MethylPREDNISolone 80 Mg/mL Injectable Suspension
- Where
- 2 sites in Puerto Rico
- Volunteers
- 20 people
- Sponsor
- Auxilio Mutuo Cancer Center
SARS-CoV 2, COVID19
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
The administration of Calcifediol in patients with COVID-19, will reduce the development of SARS and the worsening of the various phases of the syndrome.
- Conditions
- SARS-CoV 2, COVID19, SARS (Severe Acute Respiratory Syndrome), Cytokine Release Syndrome
- Trial name
- COVIDIOL (NCT04366908)
- Testing
- BAT + Calcifediol, BAT
- Where
- Spain
- Volunteers
- 517 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Acute Respiratory Distress Syndrome, Respiratory Failure
MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients
This is a phase IIa, dose-ranging, proof-of-concept study of MRG-001 in patients with ARDS. The aim is to determine the safety and preliminary efficacy of MRG-001 across two dose ranges.
- Conditions
- Acute Respiratory Distress Syndrome, Respiratory Failure, Respiratory Distress Syndrome, Respiratory Tract Diseases
- Trial name
- SUMMIT (NCT06308926)
- Testing
- MRG-001 (Low-dose), MRG-001 (High-dose)
- Volunteers
- 60 people
- Sponsor
- MedRegen LLC
COVID-19
A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care
In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, China. The pathogen was soon identified as a novel coronavirus (SARS-CoV-2), which is closely related to severe acute respiratory…
- Trial name
- NCT05195749
- Testing
- 101-PGC-005 ('005) + SOC
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- 101 Therapeutics
DHA as Antioxidant Anti-inflammatory Immunomodulation , Overcome Cytokine Storm
Observational Study of Infants Fed on DHA (Breast Source or Milk Formula Source ) and Its Effects on Covid-19 Infected Infants and Severity
Observational Study of Infants Fed on DHA (Breast Source or Milk Formula Source ) and Its Effect on COVID-19 Severity Amr kamel khalil Ahmed ( drmedahmed@gmail.com ) Director of tuberculosis program Ghubera, public health…
- Trial name
- NCT05071690
- Where
- 2 sites in Egypt, Saudi Arabia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ministry of Health, Saudi Arabia
SARS-CoV 2 Pneumonia
Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19).
Descriptive, retrospective, observational, anonymous, study to evaluate the potential effect of incorporating calcifediol into the therapeutic protocol of patients hospitalized for COVID-19 on mortality and other outcome…
- Trial name
- COVIDIOL (NCT06279910)
- Testing
- Calcifediol
- Where
- Spain
- Volunteers
- 230 people
- Sponsor
- Complejo Hospitalario Universitario de Albacete
Severe Acute Respiratory Syndrome Coronavirus 2
Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection
It is an observational, cohort, retrospective, monocentric, non-profit study. The primary objective is to evaluate the efficacy and safety of ruxolitinib in acute respiratory distress syndrome in patients with SARS-CoV-2 COVID-19…
- Trial name
- RESPIRE (NCT04361903)
- Testing
- Ruxolitinib Oral Tablet
- Volunteers
- 13 people
- Sponsor
- Azienda USL Toscana Nord Ovest
COVID-19 Pneumonia
Multiparametric Assessment of Peripheral Blood and Tissue Myeloid Cells. Phenotype for Precision Medicine in Patients With SARS-Cov-2 Infection
We hypothesise that patients with SARS-Cov-2 infection are characterized by progressive changes in distribution of distinct lung macrophages populations mediated by influx of circulating monocytes into the lungs .
- Trial name
- NCT05767853
- Testing
- Immune-phenotyping of tissue and peripheral blood myeloid compartment
- Where
- 2 sites in Italy, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
COVID-19
The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia
A randomized controlled pilot study on the safety \& efficacy of imatinib for the treatment of patient with moderate to severe SARS-COV-2 induced pneumonia.
- Trial name
- NCT04422678
- Testing
- Imatinib Mesylate, Standard of Care
- Volunteers
- 30 people
- Sponsor
- Alexandria University
COVID-19 Pnemonia
Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS)
Phase 2/3 randomized, parallel group, 2-arm study (treatment vs. control), investigating the efficacy and safety of intravenous administration of anakinra, an interleukin 1 receptor antagonist ( IL-1), added to standard…
- Trial name
- ANA-COVID-GEAS (NCT04443881)
- Testing
- Anakinra 149 MG/ML Prefilled Syringe [Kineret]
- Where
- 12 sites in Spain
- Volunteers
- 179 people
- Sponsor
- Fundacion Miguel Servet
Corona Virus Infection, Middle East Respiratory Syndrome (MERS)
Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease
The aim of the study is to clinically use bovine Lf as a safe antiviral adjuvant for treatment and to assess the potential in reducing mortality and morbidity rates in COVID-19 patients.
- Conditions
- Corona Virus Infection, Middle East Respiratory Syndrome (MERS), Acute Respiratory Distress Syndrome, Coronavirus Infection
- Trial name
- COVID-19_LF (NCT04412395)
- Testing
- Lactoferrin (Apolactoferrin)
- Where
- 4 sites in Egypt
- Volunteers
- 516 people
- Sponsor
- National Research Centre, Egypt
COVID-19
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS)…
- Trial name
- NCT04351243
- Testing
- Gimsilumab
- Where
- 33 sites in United States
- Volunteers
- 227 people
- Sponsor
- Kinevant Sciences GmbH
Coronavirus, COVID
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
This was a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care (SOC), compared with placebo plus SOC, in participants with respiratory signs and…
- Conditions
- Coronavirus, COVID, ARDS, Cytokine Storm
- Trial name
- NCT04415073
- Testing
- SNDX-6352
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Syndax Pharmaceuticals